ZD6126
Systematic (IUPAC) name | |
---|---|
Phosphoric acid mono-(5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl) ester | |
Identifiers | |
CAS Number | 219923-05-4 |
PubChem | CID 9896434 |
ChemSpider | 8072099 |
UNII | GBO3S6M9W7 |
Synonyms | ANG 453; AZD 6126; N-Acetylcolchicinol dihydrogenphosphate |
Chemical data | |
Formula | C20H24NO8P |
Molar mass | 437.38 g/mol |
| |
| |
(what is this?) (verify) |
ZD6126 is a vascular-targeting agent and a prodrug of N-acetylcolchinol, related to colchicine.[1] It has shown promising results on tumors in mice.[2]
A phase I clinical trial identified gastrointestinal and cardiac effects as limiting dosing.[3] Two phase II clinical trials were started investigating ZD6126 in metastatic renal cell carcinoma and metastatic colorectal cancer.[4] [5]
ZD6126 was being investigated by AstraZeneca as a vascular disrupting agent (VDA). However, the trials were halted, after it became apparent that ZD6126 was too cardiotoxic at the required doses.[6]
References
- ↑ ZD6126, National Cancer Institute summary
- ↑ Hisatsugu Goto, Seiji Yano, Helong Zhang, Yuka Matsumori, Hirohisa Ogawa, David C. Blakey and Saburo Sone (1 July 2002). "Activity of a New Vascular Targeting Agent, ZD6126, in Pulmonary Metastases by Human Lung Adenocarcinoma in Nude Mice". Cancer Research 62 (13): 3711–3715. PMID 12097279.
- ↑ LoRusso Patricia M; Gadgeel Shirish M; Wozniak Antoinette; Barge Alan J; Jones Helen K; DelProposto Zachary S; DeLuca Pamela A; Evelhoch Jeffrey L; Boerner Scott A; Wheeler Catherine (2008). "Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors". Investigational new drugs 26 (2): 159–67. doi:10.1007/s10637-008-9112-9. PMID 18219445.
- ↑ astrazenecaclinicaltrials.com
- ↑ ZD6126, National Institutes of Health summary
- ↑ Lippert John W. III (2007). "Vascular disrupting agents". Bioorganic & Medicinal Chemistry 15 (2): 605-615.
This article is issued from Wikipedia - version of the Sunday, April 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.